血小板源生长因子受体与肿瘤-生命科学.pdf

18 3 Vol. 18, No. 3 2006 6 Chinese Bulletin of Life Sciences Jun., 2006 1004-0374(2006)03-0220-07 · · 1 201203 2 100049 (platelet-derived growth factor, PDGF)(platelet-derived growth fac- tor receptor, PDGFR)PDGF PDGFR PDGF PDGFR PDGFR PDGFR PDGFR imatinib PDGFR Q516; R730.59A Platelet-derived growth factor receptor and cancer 1,2 1 1 ZHANG Xiu-Hua , LIN Li-Ping , DING Jian * (1 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China; 2 Graduate School of CAS, Beijing 100049, China) Abstract: Platelet-derived growth factors (PDGFs) exert their cellular effects through their receptors (PDGFRs). PDGF and PDGFR have been implicated in the pathogenesis of a number of tumor types and play important roles in angiogenesis. Tumor growth can be promoted by PDGF via autocrine stimulation of malignant cells, overexpression or overactivation of PDGFRs, or stimulation of angiogenesis within the tumor. PDGFR blockade may also lower the interstitial fluid pressure within solid tumors and enhance drug delivery. These mechanisms suggest that PDGFR antagonists play possible and feasible therapeutic roles in the treatment of cancer, alone and in combination with chemotherapy or other targeting agents. Due to the success of PDGFR antagonist imatinib developments during the last years, the interests for PDGFRs as cancer drug targets will be dramati- cally improved. Key w